26 May 06
Although ventricular and atrial fibrillation represent the most common cardiac arrhymias and are associated with amongst the highest rates of cardiovascular morbidity and mortality, treatment options are suboptimal. New opportunities are however approaching the market, notably Cardiomeâ€™s RSD1235, paving the way for development by others.
24 May 06
DailyUpdates 24th May, 2006: With the threat of influenza hanging over our heads on a seemingly continuous basis, improving the ability to rapidly and accurately identify patients infected with influenza and furthermore the strain of virus remains paramount. Today we feature research from CombiMatrix concerning their activities in this area. We also headline news coming out of Denmark's Genmab announcing the advance of HuMax-CD20, the company's CD20 monoclonal, into the clinic for the treatment
22 May 06
DailyUpdates 18th May, 2006: As the antidepressant sector continues to go through a period of turbulance we report on new data for one blockbuster from this class - Lexapro. Selected for special mention from over 50 journal articles today's feature demonstrates great timing appearing at the same time as our feature - Major Depressive Disorder. Today's edition of DailyUpdates can be seen here
19 May 06
DailyUpdates 19th May, 2006: Today's edition of DailyUpdates (see it in full here) carries a couple of important articles on renal disease. One loks at the outcome of patients with renal dysfunction across various acute coronary syndromes. The featured article however demonstrates the efficacy of Novartis' Benazepril in treating advanced renal disease
17 May 06
Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
15 May 06
DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
15 May 06
When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
13 May 06
This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, â€śOnly one thing is certain and that is that there will be a pandemic.â€ť
12 May 06
DailyUpdates 12th May, 2006 (click here for entire bulletin): Today appears to be cancer vaccine day with two important announements being made. First off, Genitope Corporation announce the initiation of an ealry phase clinical trial of their MyVax idiotype immunotherapy; this was followed by an announcement by Biovest reporting that fast track status had been awarded to their phase 3 candidate, BiovaxID. This follows in the footsteps of the company's announcement that the FDA had approved sale
11 May 06
A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
10 May 06
Marketing and PR can play a variety of roles to support a company as it develops medicines in the modern healthcare setting. Therefore it is important that companies develop suitable Marketing and PR strategies to assist them in their business and understand how they can benefit from the tools used in these functions.
Dr Faiz Kermani
10 May 06
This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited
25 Apr 06
Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
25 Apr 06
The Definitive Conference for Clinical Research Contract Professionals!
06 Apr 06
Given its proximity to the huge US market, Canada is often overlooked with respect to its contribution to the pharmaceutical sector. Yet it is a well-established market in which all the major players are active and it has a vibrant R&D environment, both for traditional pharmaceutical companies and emerging biotech companies.
Dr Faiz Kermani
06 Apr 06
Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but in recent times this attitude appears to have changed. Key mergers currently underway include Sankyo and Daiichi Pharmaceutical, Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical (who now operate as Astellas), and a tie-up between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dr Faiz Kermani
06 Apr 06
China is a country that is rapidly modernising and as its economy grows its consumer base is changing. Many international biopharmaceutical companies have started to invest in China and believe that in the long-term the healthcare market offers huge commercial potential.
Dr Faiz Kermani
30 Mar 06
Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
29 Mar 06
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
28 Mar 06
Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
23 Mar 06
e-Clinical Trials continue to be used more and more by the market leaders - There is no doubt though that the industry is soon to go fully electronic, so don't get behind the game...
Our delegates have been demanding we run this event for the last 6 years! Here is what they have said about our past events:
"...one of the best. I have learned a great deal about many of the important issues associated with e-Clinical Trials", Clinical Trial Manager/EDC Liason, Forest Labs Inc.
22 Mar 06
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.Â The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.Â Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
21 Mar 06
If Sales Force Effectiveness is high on your agenda in the current climate, then donâ€™t miss Pharma IQâ€™s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
03 Mar 06
PharmiWeb recently asked Merck to provide some insight into what it was like to work as a sales rep for their company. Rather than just telling us what they thought we wanted to hear, they took the more open approach of asking their team for "real life" comments, and then gave us their rather impressive raw responses, with no additions or changes.
01 Mar 06
Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
28 Feb 06
ICONâ€™s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.